Group 1 - The core point of the article is that Bohui Innovation (SZ 300318) held a temporary board meeting on December 1, 2025, to discuss the election of a new audit committee member and other related documents [1] - For the first half of 2025, Bohui Innovation's revenue composition was 71.68% from blood products and 28.32% from in vitro diagnostics [1] - As of the time of reporting, Bohui Innovation's market capitalization was 5.8 billion yuan [1]

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-045 北京博晖创新生物技术集团股份有限公司 关于变更董事、选举职工董事及补选董事会专门委员会委员 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、完成变更非独立董事情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 12 月 1 日召开 2025 年第一次临时股东大会，审议通过《关于补选非 独立董事的议案》，刁举鹏先生当选公司第八届董事会非独立董事，任期自 2025 年第一次临时股东大会审议通过之日起至第八届董事会任期届满之日止。 二、选举职工代表董事的情况 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范 性文件及《公司章程》等相关规定，公司于 2025 年 12 月 1 日召开了 2025 年第 一次职工代表大会，经与会职工代表审议，会议选举李洁芳女士（简历详见附件） 为第八届董事会职工代表董事，任期自公司 2025 年第一次职工代表大会通 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-044 北京博晖创新生物技术集团股份有限公司 2025 年第一次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情况； 2、本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）2025 年第一 次临时股东大会于 2025 年 12 月 1 日（星期一）下午 14：00 在公司会议室以现 场投票和网络投票相结合的形式召开。通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 12 月 1 日 9:15—9:25，9:30—11:30 和 13:00—15:00， 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 1 日 9:15 至 15:00 期间的任意时间。 本次股东大会由公司董事会召集，董事长沈治卫先生主持，公司董事、监事、 高级管理人员及律师等相关人士出席了本次会议。会议的召集、召开与表决程序 符合有关法律、行 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京博晖创新生物技术集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]A0582号 致：北京博晖创新生物技术集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《北京博晖创新生物 技术集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集 与召开程序、召集人资格、出席会议人员资格、会 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-046 表决结果：7 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 北京博晖创新生物技术集团股份有限公司 第八届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 12 月 1 日召开 2025 年第一次临时股东大会，补选刁举鹏先生为公司 第八届董事会非独立董事，并于同日召开 2025 年第一次职工代表大会，选举产 生职工代表董事李洁芳女士，第八届董事会的成员已按照有关规定调整完毕。因 情况紧急，为保证董事会工作的顺利衔接和平稳运行，公司第八届董事会第十六 次会议（以下简称"本次会议"）经全体董事一致同意豁免会议通知时限要求， 会议通知于同日以电话、口头等方式送达全体董事。本次会议于 2025 年 12 月 1 日在公司会议室召开，会议由公司董事长沈治卫先生主持，会议采取现场和通讯 表决相结合方式进行，本次会议应出席董事 7 人，实际出席董 ...

Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

证券之星消息，11月20日生物制品板块较上一交易日下跌0.54%，博晖创新领跌。当日上证指数报收于 3931.05，下跌0.4%。深证成指报收于12980.82，下跌0.76%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920047 | 诺思兰德 | 26.00 | 3.54% | 3.88万 | | 1.01亿 | | 688293 | 奧浦迈 | 58.95 | 2.22% | 1.22万 | | 7170.35万 | | 688331 | 荣昌生物 | 88.89 | 1.40% | 3.27万 | | 2.91亿 | | 300142 | 沃森生物 | 12.54 | 1.37% | 54.60万 | | 6.97亿 | | 616889 | 欧林生物 | 22.80 | 1.11% | 2.28万 | | 5169.70万 | | 688136 | 科兴制药 | 33.70 | 0.60% | 1.30万 | | 4387.18万 | ...

New Stock Offerings - Tianpu Co., Ltd. (605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] - Hangzhou Steam Turbine Co., Ltd. (200771) has a cash option declaration period from November 19, 2025, to November 25, 2025[1] - Hailianxun (300277) and Antai Group (600408) have recent announcements regarding their stock activities[1] Market Volatility - Moen Electric (002451) reported severe abnormal fluctuations with a change of 4%[1] - ST Yuancheng (603388) and ST Keli Da (603828) also reported significant fluctuations of 4% and 3% respectively[1] - ST Jianyi (002789) and Huaxia Happiness (600340) both experienced fluctuations of 7%[1] Recent Announcements - Various companies including Longzhou Co., Ltd. (002682) and Jinyuan Co., Ltd. (000546) have made announcements with fluctuations of 2% and 8% respectively[1] - The stock of Kangzhi Pharmaceutical (300086) showed a significant fluctuation of 85%[1] - Other companies like ST Yangguang (000608) and ST Jieneng (000820) reported fluctuations of 5% and 3% respectively[1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]